Boehringer Ingelheim Press Releases

Study showed new episodes of depression delayed in people taking Duloxetine

Winners announced for 2008 Eloquium Award

First pivotal trials begin for Boehringer Ingelheim’s novel triple angiokinase inhibitor Vargatef™ (BIBF 1120)

Longest follow-up period for any new oral anticoagulant explores Pradaxa® (dabigatran etexilate) for stroke prevention in atrial fibrillation (AF)

Closing in on the cause of diabetes

Telmisartan (Micardis®) as effective as ramipril but with better long-term tolerability in high-risk cardiovascular Asian patients

From Curiosity to Discovery:
Boehringer Ingelheim broadens oncology pipeline with promising new data for potentially first in class Plk1 inhibitor

From Curiosity to Discovery:
Boehringer Ingelheim`s pipeline update unveils novel investigational compounds heralding the Company`s entry into Type 2 Diabetes

ERS COPD Research Award 2008 sponsored by Boehringer Ingelheim

COPD landmark trial UPLIFT® proves tiotropium sustains lung function improvements over four years and improves survival rate

Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme

Recent research shows significant benefits in acute ischaemic stroke with Actilyse® beyond currently approved three hour treatment window

Landmark UPLIFT® study reaffirms the safety of Spiriva® (tiotropium) in patients with Chronic Obstructive Pulmonary Disease

Positive UK health technology appraisal for novel oral anticoagulant Pradaxa® (dabigatran etexilate)

Established safety profile of Spiriva® confirmed by 30 rigorously controlled clinical trials

Landmark research heralds new era in dog heart treatment and longer life for dogs